Back to Search
Start Over
Application of ProTide Technology to Gemcitabine:A Successful Approach to Overcome the Key Cancer Resistance MechanismsLeads to a New Agent (NUC-1031) in Clinical Development.
- Source :
-
Journal of Medicinal Chemistry . Feb2014, Vol. 57 Issue 4, p1531-1542. 12p. - Publication Year :
- 2014
-
Abstract
- Gemcitabineis a nucleoside analogue commonly used in cancer therapybut with limited efficacy due to a high susceptibility to cancer cellresistance. The addition of a phosphoramidate motif to the gemcitabinecan protect it against many of the key cancer resistance mechanisms.We have synthesized a series of gemcitabine phosphoramidate prodrugsand screened for cytostatic activity in a range of different tumorcell lines. Among the synthesized compounds, one in particular (NUC-1031, 6f) was shown to be potent in vitro. Importantly,compared with gemcitabine, 6factivation was significantlyless dependent on deoxycytidine kinase and on nucleoside transporters,and it was resistant to cytidine deaminase-mediated degradation. Moreover, 6fshowed a significant reduction in tumor volumes in vivoin pancreatic cancer xenografts. The ProTide 6fis now in clinical development with encouraging efficacysignals in a Phase I/II study, which strongly supports the ProTideapproach to generate promising new anticancer agents. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00222623
- Volume :
- 57
- Issue :
- 4
- Database :
- Academic Search Index
- Journal :
- Journal of Medicinal Chemistry
- Publication Type :
- Academic Journal
- Accession number :
- 94765749
- Full Text :
- https://doi.org/10.1021/jm401853a